2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001...

58
2001 DEY B9-508-00 7/01

Transcript of 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001...

Page 1: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

2001 DEY B9-508-00 7/01

Page 2: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Anaphylaxis:

Screen, Educate, and Protect to Improve Patient Outcomes

2001 DEY B9-508-00 7/01

Page 3: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Definition of Anaphylaxis

• Systemic allergic reaction

– Affects body as a whole

– Multiple organ systems may be involved

• Onset generally acute

• Manifestations vary from mild to fatal

Page 4: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Myth: Anaphylaxis Is Rare

REALITY:

• Anaphylaxis is underreported

• Incidence seems to be increasing

• Up to 41 million Americans at risk (Neugut AI et al, 2001)

• 63,000 new cases per year (Yocum MW et al, 1999)

• 5% of adults may have a history of anaphylaxis (various surveys)

Page 5: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Pathogenesis of Anaphylaxis

• IgE-mediated (Type I hypersensitivity)

• Sensitization stage

• Subsequent anaphylactic response

Page 6: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Sensitization Stage

Antigen (allergen) exposure

Plasma cells produce IgE antibodies against the allergen

IgE antibodies attach to mast cells and basophils

Mast cell withfixed IgE antibodies

IgE

Granules containing histamine

Antigen

Plasma cell

Page 7: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Anaphylactic Reaction

More of same allergen invades body

Antigen

Mast cell granules release contents after antigen binds with IgE antibodies

Histamine and other mediators

.••

•••

•••

•• •

•••••

•• •

•••

•••••

••• •

•••••

••• •

•• •

••••

•• •

• •

•••

•••••

••

••

••

•• •

••

••

••

•••••

••• •

•• •

••••

•• •

•••

••

••

•••

••

••

••

•• ••

•••••

••

•••

••

••

•• •

•••

•••••

••

••

• •

•• •

••

•••

••• •

••

••

••

••

••

•••

•• ••

•• •

• •• ••

••••

••• •

••

• • •

••

Allergen combines with IgE attached to mast cells and basophils, which triggers degranulation and release of histamine and other chemical mediators •

••

••

Page 8: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Common Causes of IgE-mediated Anaphylaxis

• Foods• Insect venoms• Latex• Medications• Immunotherapy

– Insect venom– Inhalant allergens

Page 9: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Anaphylactoid Reactions

• Non–IgE-mediated

– Complement-mediated

• Anaphylatoxins, eg, blood products

– Direct stimulation

• eg, radiocontrast media

– Mechanism unknown

• Exercise

• NSAIDs

Page 10: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Myth: The Cause of Anaphylaxis is Always Obvious

REALITY:

• Idiopathic anaphylaxis is common

• Triggers may be hidden– Foods

– Latex

• Patient may not recall details of exposure, clinical course

Page 11: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Clinical Manifestations of Anaphylaxis

• Skin: Flushing, pruritus, urticaria, angioedema

• Upper respiratory: Congestion, rhinorrhea

• Lower respiratory: Bronchospasm, throat or

chest tightness, hoarseness, wheezing,

shortness of breath, cough

Page 12: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Clinical Manifestations of Anaphylaxis

• Gastrointestinal tract:

– Oral pruritus

– Cramps, nausea, vomiting, diarrhea

• Cardiovascular system:

– Tachycardia, bradycardia,

hypotension/shock, arrhythmias,

ischemia, chest pain

Page 13: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Clinical Manifestations of Anaphylaxis

Signs/symptoms Incidence (%)

Urticaria and angioedemaUpper airway edema*Dyspnea and wheezingFlush*Dizziness, syncope, and hypotensionGastrointestinal symptomsRhinitis*Headache*Substernal pain*Itch without rash*Seizure*

*Symptom or sign not reported in all four series

8856474633301615

64.5

1.5

Page 14: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Myth: Anaphylaxis Always Presents with Cutaneous Manifestations

REALITY:• Approximately 10%-20% of anaphylaxis

cases will not present with hives or other cutaneous manifestations

• 80% of food-induced, fatal anaphylaxis cases were not associated with cutaneous signs or symptoms

Page 15: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Clinical Course of Anaphylaxis

• Uniphasic

• Biphasic

– Recurrence up to 8 hours later

• Protracted

– Hours to days

Page 16: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Myth: Prior Episodes Predict Future Reactions

REALITY:

• No predictable pattern

• Severity depends on:– Sensitivity of the individual – Dose of the allergen

Page 17: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Anaphylaxis Fatalities

• Estimated 500–1000 deaths annually• 1% risk • Risk factors:

– Failure to administer epinephrine immediately

– Beta blocker, ?ACEI therapy– Asthma– Cardiac disease– Rapid IV allergen

Page 18: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Food-induced Anaphylaxis: Incidence

• 35%–55% of anaphylaxis is caused by food allergy

• 6%–8% of children have food allergy

• 1%–2% of adults have food allergy

• Incidence is increasing

• Accidental food exposures are

common and unpredictable

Page 19: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Food-induced Anaphylaxis: Common Triggers

• Children and adults (usually not outgrown):

– Peanuts

– Tree nuts

– Shellfish

– Fish

• Additional triggers in children (commonly outgrown):

– Milk

– Egg

– Soy

– Wheat

Page 20: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Food-induced Anaphylaxis: Common Symptoms

• Oropharynx: Oral pruritus, swelling of lips

and tongue, throat tightening

• GI: Crampy abdominal pain, nausea,

vomiting, diarrhea

• Cutaneous: Urticaria, angioedema

• Respiratory: Shortness of breath,

stridor, cough, wheezing

Page 21: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Food-induced Anaphylaxis: Fatal Reactions

• Fatal reactions are on the rise

– ~150 deaths per year

– Usually caused by a known allergy

• Patients at risk:

– Peanut and tree nut allergy

– Asthma

– Prior anaphylaxis

– Failure to treat promptly w/epinephrine

• Many cases exhibit biphasic reaction

Page 22: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Fatal Food-induced Anaphylaxis (Bock SA, et al. JACI 2001;107:191–193)

• 32 cases of fatal anaphylaxis

• Adolescents or young adults

• Peanuts, tree nuts caused >90% of Rxn

• 20 of 21 with complete history had asthma

• Most did not have epinephrine available

Page 23: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Food-induced Anaphylaxis: Prevention

• Learn to read product labels

– Identify alternative names for ingredients

– Find “hidden” ingredients

• Avoid high-risk foods (eg, baked goods)

• Avoid sharing food, utensils, or food containers

– Minute amounts can be life-threatening

• Provide educational materials

– FAAN- (www.foodallergy.org)

I. AVOID ALLERGENS

Page 24: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Food-induced Anaphylaxis: Prevention

• Complete avoidance is impossible

• Must always be prepared to treat a reaction

– Have an emergency action plan

– Keep EpiPen or EpiPen Jr on hand at all times

– Train caregivers and teachers on EpiPen use

– Wear MedicAlert bracelet

II. RISK MANAGEMENT

Page 25: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Venom-induced Anaphylaxis: Incidence

• 0.5%–5% (13 million) Americans are

sensitive to one or more insect venoms • Incidence is underestimated• Incidence increasing due to fire ants and

Africanized bees• Incidence rising due to more outdoor activities• At least 40–100 deaths per year

Page 26: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Venom-induced Anaphylaxis: Common Culprits

• Hymenoptera– Bees – Wasps– Yellow jackets– Hornets– Fire ants

• Geographical– Honeybees, yellow jackets most common in East,

Midwest, and West regions of US– Wasps, fire ants most common in Southwest

and Gulf Coast

Page 27: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Venom-induced Reactions: Common Symptoms

• Normal: Local pain, erythema, mild swelling

• Large local: Extended swelling, erythema• Anaphylaxis: Usual onset within 15–20 minutes

– Cutaneous: urticaria, flushing, angioedema

– Respiratory: dyspnea, stridor

– Cardiovascular: hypotension, dizziness, loss of consciousness

• 30%–60% of patients will experience a systemic reaction with subsequent stings

Page 28: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Venom-induced Anaphylaxis: Prevention

Avoidance Measures

What to do What not to doHave professionals Use scented productsremove hives or nests

Wear bright colorsWear white, smooth- finish clothes, ankle- Go barefoothigh shoes

Drink from open cansKeep outdoor areas free when contents are notof garbage visible

Page 29: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Venom-induced Anaphylaxis: Prevention

Risk Management

• Keep EpiPen or EpiPen Jr on hand at all times

• Educate and train on EpiPen use

• Develop emergency action plan

• Wear a MedicAlert bracelet• Consult an allergist to determine need for venom

immunotherapy

Page 30: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Venom-induced Anaphylaxis: Immunotherapy

• Medical criteria– Hx of any systemic reaction in adults– Hx of life-threatening reaction in children– Positive venom skin test

• 97% effective• Can be discontinued in most after 3–5 years;

10% risk of systemic reaction to subsequent stings

Page 31: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Venom-induced Anaphylaxis: Immunotherapy

• Risk of anaphylaxis– 10%-15% of patients experience

systemic reactions during early weeks of treatment

– Sx generally occur within 20 minutes

– Patients at risk: asthma, prior reactions, beta blocker or ACEI therapy

Page 32: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Immunotherapy-induced Anaphylaxis

• Risk management

– Trained physician, equipped facility

– Epinephrine immediately available

– Monitor closely for 20–30 minutes – Consider supply of EpiPen for those at

high risk

Page 33: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Latex-induced Anaphylaxis: Incidence

• 1%–6% of US population (up to 16 million)

affected

• 8%–17% incidence among health care workers

• Repeated exposure leads to a higher risk

• Incidence has increased since mid 1980s

– Latex gloves, especially powdered gloves

Page 34: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Latex-induced Anaphylaxis: Triggers

• Proteins in natural rubber latex

• Component of ~40,000 commonly used items

– Rubber bands

– Elastic (undergarments)

– Hospital and dental equipment

• Latex-dipped products are biggest culprits

– Balloons, gloves, bandages, hot water bottles

Page 35: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Reactions to Latex

• Irritant contact dermatitis

– Dry, itchy, irritated hands

• Allergic contact dermatitis

– Delayed hypersensitivity

• Latex allergy

– Immediate hypersensitivity

– Sx: hives, itching, sneezing, rhinitis, dyspnea, cough,

wheezing

– Greatest risk with mucosal contact

Page 36: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Latex-induced Anaphylaxis: Prevention

• Use latex-free products

• Alert employer/health care providers, schools about need for latex-free products and equipment

• Wear MedicAlert bracelet

• Awareness of cross-sensitivity with foods:

I. AVOIDANCE

– Banana– Avocado– Chestnuts

– Kiwi– Stone fruit– Others

Page 37: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Latex-induced Anaphylaxis: Prevention

• Prescribe EpiPen® or EpiPen® Jr

– Accidental exposure

– Patients at risk• Educate re: EpiPen® use• Develop emergency action plan

II. RISK MANAGEMENT

Page 38: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Other Causes of Anaphylacticand Anaphylactoid Reactions

• Drugs

– Antibiotics

– Chemotherapeutic agents

– Aspirin, NSAIDs

– Biologicals (vaccines, monoclonal antibodies)

• Radiocontrast media

• Exercise

• Idiopathic

Page 39: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Diagnosing Anaphylaxis

• Based on clinical presentation, exposure Hx

• Cutaneous, respiratory Sx most common

• Some cases may be difficult to diagnose

– Vasovagal syncope

– Scombroid poisoning

– Systemic mastocytosis

Page 40: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Diagnosing Anaphylaxis

• Careful history to identify possible causes

• Can be confirmed by serum tryptase

– Specific for mast cell degranulation

– Remains elevated for up to 6 hours

• Other labs to rule out other diagnoses

• Refer to allergist for specific testing

Page 41: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Diagnosing Anaphylaxis

• Skin tests/RAST– Foods– Insect venoms– Drugs

• Challenge tests– Foods– NSAIDs– Exercise

Allergists can identify specific causes by:

Page 42: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Treatment of Anaphylaxis

• Immediate treatment with epinephrine imperative– No contraindications in anaphylaxis– Failure or delay associated with fatalities– IM may produce more rapid, higher peak levels

vs SC– Must be available at all times

• Antihistamine (oral or parenteral; if oral, use liquid or chewable tablet)

• Call 911; proceed to Emergency Room

Page 43: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

EpiPen/EpiPen Jr: Directions for Use

Page 44: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

EpiPen/EpiPen Jr: Directions for Use

Page 45: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

EpiPen/EpiPen Jr: Directions for Use

Page 46: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Myth: Epinephrine is Dangerous

REALITY:

• Risks of anaphylaxis far outweigh risks of epinephrine administration

• Minimal cardiovascular effects in children (Simons et al, 1998)

• Caution when administering epinephrine in elderly patients or those with known cardiac disease

Page 47: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Treatment of Anaphylaxis

• Additional measures may include

– Corticosteroids

– Supplemental O2; airway maintenance

– IV fluids, vasopressor therapy

– Repeat epinephrine if Sx persist or increase after 10-15 minutes

– Repeat antihistamine ± H2 blocker if Sx persist

– Observe for a minimum 4 hours

– Arrange follow-up care, provide EpiPen® Rx and education

Page 48: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Myth: Anaphylaxis is Reported

REALITY:

• Most individuals do not inform their personal

physician of an anaphylactic reaction either at

the time of the reaction or during routine exams

Page 49: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Risk Management for Anaphylaxis

• SCREEN

– Atopy

• 10% of children with asthma have food

allergy• 30%–40% of children with atopic dermatitis

have food allergy

– Previous reactions

• 75% will have more than one

• 57% will have three or more

Page 50: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Screening Patients at Risk

Did you ever have a severe allergic reaction:

– To any food?

– To any medicine?

– To an insect sting?

– To latex?

– That caused breathing trouble? Severe hives and

swelling? Severe vomiting or diarrhea? Dizziness?

– That required you to go to the hospital?

Page 51: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

SCREEN, Educate, and ProtectPatients at Risk

Page 52: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Risk Management for Anaphylaxis

• EDUCATE

– Teach avoidance measures

– “Accidents are never planned”

– Stress importance of:

• Always having a current EpiPen on hand

• Immediate treatment

– Emphasize the need for follow-up care

Page 53: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

EpiPen® 2-Pak

* EpiPen® 2-Pak was launched in April 2001

Page 54: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Risk Management for Anaphylaxis

• EDUCATE: Draft an Emergency Plan

– Provide specific instructions on when to

administer EpiPen or EpiPen Jr

– Call for help (911); transport patient to emergency

care facility

– Stay calm; keep patient warm

– Specify directions for antihistamine use

– Report EpiPen administration

Page 55: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Screen, Educate, and Protect

AAAAI Board of Directors. Position statement: Anaphylaxis in schools and other childcare settings. J Allergy Clin Immunol 1999;102:173-176. Reprinted with permission.

Emergency Health Care PlanALLERGY TO:_____________________________________________________________

Child’sName:___________________________D.O.B:____________Teacher:___________________

Asthmatic Yes (High risk for severe reaction) No

Signs of an allergic reaction include:

Systems: Symptoms:

•MOUTH itching & swelling of the lips, tongue, or mouth

•THROAT* itching and/or a sense of tightness in the throat, hoarseness, and hacking cough

•SKIN hives, itchy rash, and/or swelling about the face or extremities

•GUT nausea, abdominal cramps, vomiting, and/or diarrhea

•LUNG* shortness of breath, repetitive coughing, and/or wheezing

•HEART* “thready” pulse, “passing-out”

The severity of symptoms can quickly change! *All above symptoms can potentially progress to a life-threatening situation!

ACTION:

1. If ingestion is suspected give________________________________________________ medication/dose/route

and_____________________________________________________immediately! 2. CALL RESCUE SQUAD:_________________________________________________

3. CALL: Mother__________________ Father___________________ or emergency contacts

4. CALL: Dr.____________________________ at ____________________________DO NOT HESITATE TO ADMINISTER MEDICATION OR CALL RESCUE SQUAD

EVEN IF PARENTS OR DOCTOR CANNOT BE REACHED!

________________________ _______ _______________________M.D. _______ Parent Signature Date Doctor’s Signature Date

For children with multiple food allergies, use one form for each food.

Emergency Health Care PlanALLERGY TO:_____________________________________________________________

Child’sName:___________________________D.O.B:____________Teacher:___________________

Asthmatic Yes (High risk for severe reaction) No

Signs of an allergic reaction include:

Systems: Symptoms:

•MOUTH itching & swelling of the lips, tongue, or mouth

•THROAT* itching and/or a sense of tightness in the throat, hoarseness, and hacking cough

•SKIN hives, itchy rash, and/or swelling about the face or extremities

•GUT nausea, abdominal cramps, vomiting, and/or diarrhea

•LUNG* shortness of breath, repetitive coughing, and/or wheezing

•HEART* “thready” pulse, “passing-out”

The severity of symptoms can quickly change! *All above symptoms can potentially progress to a life-threatening situation!

ACTION:

1. If ingestion is suspected give________________________________________________ medication/dose/route

and_____________________________________________________immediately! 2. CALL RESCUE SQUAD:_________________________________________________

3. CALL: Mother__________________ Father___________________ or emergency contacts

4. CALL: Dr.____________________________ at ____________________________DO NOT HESITATE TO ADMINISTER MEDICATION OR CALL RESCUE SQUAD

EVEN IF PARENTS OR DOCTOR CANNOT BE REACHED!

________________________ _______ _______________________M.D. _______ Parent Signature Date Doctor’s Signature Date

For children with multiple food allergies, use one form for each food.

EMERGENCY CONTACTS TRAINED STAFF MEMBERS

1.__________________________________

Relation:________________Phone:________

1._________________________Room______

2.__________________________________

Relation:________________Phone:________

2._________________________Room______

3.__________________________________

Relation:________________Phone:________

3._________________________Room______

PlaceChild’sPictureHere

Page 56: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Myth: Anaphylaxis is Easy to Avoid If You Know What You are Allergic To

REALITY:

• Most cases of anaphylaxis are due to accidental exposures

Page 57: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Risk Management for Anaphylaxis

• PROTECT:

– Prescribe self-injectable EpiPen

– Teach patient proper use of EpiPen

– Educate family, friends, teachers, caregivers

Page 58: 2001 DEY B9-508-00 7/01. Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes 2001 DEY B9-508-00 7/01.

Anaphylaxis

Screen, educate, and protect

+

Immediate treatment

=

Saved lives